These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 19591406

  • 1. [Chronological change in the national health insurance reimbursement based on the DPC package payment system regarding 131I internal therapy].
    Kunishima M, Sakaguchi C, Kita T, Watanabe S, Yano F, Soga S, Shinmoto H, Kosuda S.
    Kaku Igaku; 2008 May; 45(2):115-8. PubMed ID: 19591406
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Cost-utility analysis of antithyroid drug therapy versus 131I therapy for Graves' disease].
    Hayashi K, Abe K, Sakata I, Sakaguchi C, Yamamoto K, Kosuda S.
    Kaku Igaku; 2005 May; 42(2):87-95. PubMed ID: 16038427
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Recent progress in radionuclide therapy].
    Kasagi K, Iwata M, Misaki T, Konishi J, Sakahara H.
    Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Nov; 60(13):729-37. PubMed ID: 11140321
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An economic analysis of managed fee-for-service and direct reimbursement.
    van der Wal CJ, Smithwick CL.
    J Am Coll Dent; 1997 Nov; 64(3):28-36. PubMed ID: 9420385
    [Abstract] [Full Text] [Related]

  • 10. Forecasting the future reimbursement system of Korean National Health Insurance: a contemplation focusing on global budget and Neo-KDRG-based payment systems.
    Kim YK.
    J Korean Med Sci; 2012 May; 27 Suppl(Suppl):S25-32. PubMed ID: 22661867
    [Abstract] [Full Text] [Related]

  • 11. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N, Gómez Saez JM, Orti Llavería A, Gavaldá Mestre L, Mairal Pairó L, Soler Ramón J.
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [Abstract] [Full Text] [Related]

  • 12. [Approval of additional management fee in medical insurance and its change].
    Mori M.
    Rinsho Byori; 2009 Dec; 57(12):1182-5. PubMed ID: 20077819
    [Abstract] [Full Text] [Related]

  • 13. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
    Orsini F, Traino AC, Grosso M, Guidoccio F, Boni G, Volterrani D, Mariani G.
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
    [Abstract] [Full Text] [Related]

  • 14. Radiation doses to patient's relatives following radioiodine therapy.
    Sulaiman BT, Clarke SE.
    Med J Malaysia; 1996 Mar; 51(1):131-3. PubMed ID: 10967992
    [Abstract] [Full Text] [Related]

  • 15. National and local trends in CT colonography reimbursement: past, present, and future.
    Knechtges PM, McFarland BG, Keysor KJ, Duszak R, Barish MA, Carlos RC.
    J Am Coll Radiol; 2007 Nov; 4(11):776-99. PubMed ID: 17964501
    [Abstract] [Full Text] [Related]

  • 16. Blue Cross Blue Shield to restructure reimbursement.
    Tenn Med; 2004 Jun; 97(6):266. PubMed ID: 15230060
    [No Abstract] [Full Text] [Related]

  • 17. [Consequences of new patient discharge guidelines on the cost structure of radioiodine therapy].
    Dietlein M, Troche CJ, Moka D, Bausch V, Lauterbach KW, Schicha H.
    Nuklearmedizin; 1998 Jan; 37(1):33-40. PubMed ID: 9467168
    [Abstract] [Full Text] [Related]

  • 18. Case-mix payment in Japanese medical care.
    Okamura S, Kobayashi R, Sakamaki T.
    Health Policy; 2005 Nov; 74(3):282-6. PubMed ID: 16226139
    [Abstract] [Full Text] [Related]

  • 19. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I).
    Hegele RA, Volpé R.
    J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162
    [Abstract] [Full Text] [Related]

  • 20. International differences in approaches to 131I therapy for Graves' disease: case selection and restrictions recommended to patients in Japan, Korea, and China.
    Tominaga T, Yokoyama N, Nagataki S, Cho BY, Koh CS, Chen JL, Shi Y.
    Thyroid; 1997 Apr; 7(2):217-20. PubMed ID: 9133688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.